New York’s Checkpoint Therapeutics (Nasdaq: CKPT) has finished enrolling patients in a registration-enabling trial of its experimental checkpoint blocker cosibelimab.
The trial evaluates the immunotherapy as an option for people with metastatic cutaneous squamous cell carcinoma (cSCC), and has a primary efficacy endpoint of confirmed objective response rate (ORR).
Checkpoint believes its candidate is a potential best-in-class PD-L1 blocker, with a unique mechanism of action which removes the suppressive effects of PD-L1 on certain anti-tumor components of the immune system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze